Literature DB >> 1812438

Production, characterization and control of MenB-vaccine "Folkehelsa": an outer membrane vesicle vaccine against group B meningococcal disease.

J H Fredriksen1, E Rosenqvist, E Wedege, K Bryn, G Bjune, L O Frøholm, A K Lindbak, B Møgster, E Namork, U Rye.   

Abstract

A vaccine against serogroup B meningococcal disease has been prepared from a B:15:P1.7,16 meningococcal strain (44/76) by fermentor growth and extraction of the bacteria with the detergent deoxycholate. Outer membrane vesicles (OMV) were purified by ultracentrifugation and adsorbed to aluminium hydroxide adjuvant. OMV contained the major class 1, 3, 4 and 5 proteins and some minor high molecular weight protein components. Relative to protein, the vaccine also contained about 8% phospholipid, 7% lipopolysaccharide and 16% deoxycholate. The product was generally non-pyrogenic to humans in ordinary doses and was highly immunogenic in mice and humans. Production and control steps, physical, chemical and immunological data for the vaccine are described.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1812438

Source DB:  PubMed          Journal:  NIPH Ann        ISSN： 0332-5652


  80 in total

1.  Functional activities and epitope specificity of human and murine antibodies against the class 4 outer membrane protein (Rmp) of Neisseria meningitidis.

Authors:  E Rosenqvist; A Musacchio; A Aase; E A Høiby; E Namork; J Kolberg; E Wedege; A Delvig; R Dalseg; T E Michaelsen; J Tommassen
Journal:  Infect Immun       Date:  1999-03       Impact factor: 3.441

2.  Human opsonins induced during meningococcal disease recognize outer membrane proteins PorA and PorB.

Authors:  A K Lehmann; A Halstensen; I S Aaberge; J Holst; T E Michaelsen; S Sornes; L M Wetzler; H Guttormsen
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

3.  Protection by meningococcal outer membrane protein PorA-specific antibodies and a serogroup B capsular polysaccharide-specific antibody in complement-sufficient and C6-deficient infant rats.

Authors:  Maija Toropainen; Leena Saarinen; Gestur Vidarsson; Helena Käyhty
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

4.  Meningococcal outer membrane vesicle vaccine given intranasally can induce immunological memory and booster responses without evidence of tolerance.

Authors:  H Bakke; K Lie; I L Haugen; G E Korsvold; E A Høiby; L M Naess; J Holst; I S Aaberge; F Oftung; B Haneberg
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

5.  Combined administration of meningococcal serogroup B outer membrane vesicle vaccine and conjugated serogroup C vaccine indicated for prevention of meningococcal disease is safe and immunogenic.

Authors:  Ingeborg S Aaberge; Philipp Oster; Oddveig S Helland; Anne-Cathrine Kristoffersen; Ellen Ypma; E Arne Høiby; Berit Feiring; Hanne Nøkleby
Journal:  Clin Diagn Lab Immunol       Date:  2005-05

6.  Persisting immune responses indicating long-term protection after booster dose with meningococcal group B outer membrane vesicle vaccine.

Authors:  Berit Feiring; Jan Fuglesang; Philipp Oster; Lisbeth M Naess; Oddveig S Helland; Sandrine Tilman; Einar Rosenqvist; Marianne A R Bergsaker; Hanne Nøkleby; Ingeborg S Aaberge
Journal:  Clin Vaccine Immunol       Date:  2006-07

7.  Functional and specific antibody responses in adult volunteers in new zealand who were given one of two different meningococcal serogroup B outer membrane vesicle vaccines.

Authors:  E Wedege; K Bolstad; A Aase; T K Herstad; L McCallum; E Rosenqvist; P Oster; D Martin
Journal:  Clin Vaccine Immunol       Date:  2007-05-09

8.  Infection with an avirulent phoP mutant of Neisseria meningitidis confers broad cross-reactive immunity.

Authors:  J Newcombe; L-J Eales-Reynolds; L Wootton; A R Gorringe; S G P Funnell; S C Taylor; J J McFadden
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

9.  Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine.

Authors:  E Rosenqvist; E A Høiby; E Wedege; K Bryn; J Kolberg; A Klem; E Rønnild; G Bjune; H Nøkleby
Journal:  Infect Immun       Date:  1995-12       Impact factor: 3.441

10.  Influence of intravenous anesthesia on mucosal and systemic antibody responses to nasal vaccines.

Authors:  Libuse Janakova; Hilde Bakke; Inger Lise Haugen; Aud K H Berstad; E Arne Høiby; Ingeborg S Aaberge; Bjørn Haneberg
Journal:  Infect Immun       Date:  2002-10       Impact factor: 3.441
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.